CA2900604A1 - Sodium channel modulators for the treatment of pain - Google Patents

Sodium channel modulators for the treatment of pain Download PDF

Info

Publication number
CA2900604A1
CA2900604A1 CA2900604A CA2900604A CA2900604A1 CA 2900604 A1 CA2900604 A1 CA 2900604A1 CA 2900604 A CA2900604 A CA 2900604A CA 2900604 A CA2900604 A CA 2900604A CA 2900604 A1 CA2900604 A1 CA 2900604A1
Authority
CA
Canada
Prior art keywords
compound
chloro
sulfamoyl
pain
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2900604A
Other languages
English (en)
French (fr)
Inventor
Olga BABICH
Robert Z. Luo
Yanlin WANG-FISCHER
David J. Palling
Srinivasan P. Venkatachalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromocell Corp
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of CA2900604A1 publication Critical patent/CA2900604A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2900604A 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain Pending CA2900604A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787618P 2013-03-15 2013-03-15
US61/787,618 2013-03-15
PCT/US2014/025809 WO2014151472A1 (en) 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain

Publications (1)

Publication Number Publication Date
CA2900604A1 true CA2900604A1 (en) 2014-09-25

Family

ID=51580969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900604A Pending CA2900604A1 (en) 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain

Country Status (16)

Country Link
US (1) US10179781B2 (enExample)
EP (1) EP2968234B1 (enExample)
JP (1) JP6449845B2 (enExample)
KR (1) KR20150131254A (enExample)
CN (1) CN105188694B (enExample)
AU (1) AU2014234105B2 (enExample)
BR (1) BR112015022096A8 (enExample)
CA (1) CA2900604A1 (enExample)
ES (1) ES2687481T3 (enExample)
HK (1) HK1219060A1 (enExample)
IL (1) IL242564A0 (enExample)
MX (1) MX363680B (enExample)
MY (1) MY188139A (enExample)
PH (1) PH12015501740A1 (enExample)
RU (1) RU2669367C2 (enExample)
WO (1) WO2014151472A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020161606A1 (en) * 2019-02-04 2020-08-13 Simon Fraser University Methods and compounds for inhibition of inactivation of voltage-gated sodium channels

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
WO2013064983A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
CA2898679A1 (en) 2013-03-14 2014-09-25 Xenon Pharmaceuticals Inc. Substituted triazolopyridines and methods of use thereof
JP6449845B2 (ja) 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
RU2015143834A (ru) 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
MY181928A (en) * 2013-09-10 2021-01-14 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
US20170304306A1 (en) * 2014-09-09 2017-10-26 Chromocell Corporation SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
JP6987746B2 (ja) 2015-09-28 2022-01-05 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
US10441586B2 (en) 2015-10-07 2019-10-15 Arizona Board Of Regents On Behalf Of The University Of Arizona CRMP2 SUMOylation inhibitors and uses thereof
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
CA3008611A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
EP3851436B1 (en) 2018-09-10 2024-06-12 Kaken Pharmaceutical Co., Ltd. Novel heteroaromatic amide derivative and medicine containing same
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
WO2021119157A1 (en) 2019-12-11 2021-06-17 Duke University Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
HUP0401211A3 (en) * 2001-03-14 2008-03-28 Gruenenthal Gmbh Substituted pyrazoles pyrazolopyrimidines and thiazolopyrimidines, process for their preparation, their use and pharmaceutical compositions containg them
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
RU2006107211A (ru) * 2003-08-08 2007-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7649004B2 (en) * 2004-07-23 2010-01-19 Pfizer, Inc. Pyridine derivatives
KR20070068432A (ko) 2004-10-29 2007-06-29 아스트라제네카 아베 염증 질환의 치료를 위한 글루코코르티코이드 수용체조절제로서의 신규 술폰아미드 유도체
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
KR101397915B1 (ko) 2005-12-23 2014-05-26 와이어쓰 엘엘씨 개질된 리신 모방 화합물
EP2173743A2 (en) * 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
ES2523196T3 (es) 2007-07-13 2014-11-21 Icagen, Inc. Inhibidores de los canales de sodio
AU2010204118B2 (en) 2009-01-12 2012-12-20 Icagen, Inc. Sulfonamide derivatives
CA2761639C (en) 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2011133729A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors
ES2526675T3 (es) * 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
JP2014507136A (ja) 2011-01-18 2014-03-27 アムジエン・インコーポレーテツド ＮａＶ１．７ノックアウトマウスとそれらの使用
EP2744805A1 (en) 2011-08-17 2014-06-25 Amgen Inc. Heteroaryl sodium channel inhibitors
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
WO2014078479A2 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
JP6449845B2 (ja) 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
PL3417851T3 (pl) 2013-09-09 2020-12-14 Peloton Therapeutics, Inc. Etery arylowe i ich zastosowanie
MY181928A (en) 2013-09-10 2021-01-14 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020161606A1 (en) * 2019-02-04 2020-08-13 Simon Fraser University Methods and compounds for inhibition of inactivation of voltage-gated sodium channels

Also Published As

Publication number Publication date
RU2015133310A (ru) 2017-04-20
PH12015501740A1 (en) 2015-10-19
KR20150131254A (ko) 2015-11-24
AU2014234105B2 (en) 2019-01-03
HK1219060A1 (zh) 2017-03-24
ES2687481T3 (es) 2018-10-25
EP2968234B1 (en) 2018-06-27
WO2014151472A1 (en) 2014-09-25
EP2968234A4 (en) 2016-10-12
CN105188694B (zh) 2018-07-31
IL242564A0 (en) 2016-02-29
BR112015022096A8 (pt) 2019-11-26
MX2015011907A (es) 2016-05-16
US20160046617A1 (en) 2016-02-18
JP6449845B2 (ja) 2019-01-09
US10179781B2 (en) 2019-01-15
CN105188694A (zh) 2015-12-23
AU2014234105A1 (en) 2015-09-03
MX363680B (es) 2019-03-29
MY188139A (en) 2021-11-23
JP2016512844A (ja) 2016-05-09
RU2669367C2 (ru) 2018-10-11
EP2968234A1 (en) 2016-01-20
BR112015022096A2 (pt) 2017-07-18
RU2015133310A3 (enExample) 2018-02-28

Similar Documents

Publication Publication Date Title
CA2900604A1 (en) Sodium channel modulators for the treatment of pain
CA2922851C (en) Sodium channel modulators for the treatment of pain and diabetes
EP3009427B1 (en) Benzimidazole inhibitors of the sodium channel
CA2681118A1 (en) Amide derivatives as calcium channel blockers
KR20170095964A (ko) Hdac1/2 억제제로서 피페리딘 유도체
CA2688267A1 (en) Amino acid derivatives as calcium channel blockers
TW201038565A (en) Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
JP2024539268A (ja) Ｓｉｋ３阻害剤及びその中間体を調製する合成スキーム及び手順
US9975873B2 (en) Isoindoline derivatives
WO2016040315A1 (en) Selective nav1.7 inhibitors for the treatment of diabetes
TW202146381A (zh) 可用作RORγ調節劑的聯芳基類化合物
Salem et al. Synthesis and biological evaluation of orally active anti-Trypanosoma agents
HK1224572A1 (en) Sodium channel modulators for the treatment of pain and diabetes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190313

FZDE Discontinued

Effective date: 20210913

FZDC Discontinued application reinstated

Effective date: 20211216

FZDC Discontinued application reinstated

Effective date: 20211216

FZDC Discontinued application reinstated

Effective date: 20211216

FZDC Discontinued application reinstated

Effective date: 20211216

FZDC Discontinued application reinstated

Effective date: 20211216